KR20200090742A - Il-7 및 il-21에의 il-15 기반 융합 - Google Patents

Il-7 및 il-21에의 il-15 기반 융합 Download PDF

Info

Publication number
KR20200090742A
KR20200090742A KR1020207009046A KR20207009046A KR20200090742A KR 20200090742 A KR20200090742 A KR 20200090742A KR 1020207009046 A KR1020207009046 A KR 1020207009046A KR 20207009046 A KR20207009046 A KR 20207009046A KR 20200090742 A KR20200090742 A KR 20200090742A
Authority
KR
South Korea
Prior art keywords
cells
fusion protein
protein complex
soluble
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207009046A
Other languages
English (en)
Korean (ko)
Inventor
힝 씨. 웡
Original Assignee
알토 바이오사이언스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알토 바이오사이언스 엘엘씨 filed Critical 알토 바이오사이언스 엘엘씨
Publication of KR20200090742A publication Critical patent/KR20200090742A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D8/00—Methods for preparing or baking dough
    • A21D8/02—Methods for preparing dough; Treating dough prior to baking
    • A21D8/04—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes
    • A21D8/047—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes with yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01002—Beta-amylase (3.2.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01033—Amylo-alpha-1,6-glucosidase (3.2.1.33)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0106—Glucan 1,4-alpha-maltotetraohydrolase (3.2.1.60)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207009046A 2017-08-28 2018-08-28 Il-7 및 il-21에의 il-15 기반 융합 Ceased KR20200090742A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762551218P 2017-08-28 2017-08-28
US62/551,218 2017-08-28
PCT/US2018/048365 WO2019046313A1 (en) 2017-08-28 2018-08-28 IL-15 BASED FUSIONS WITH IL-7 AND IL-21

Publications (1)

Publication Number Publication Date
KR20200090742A true KR20200090742A (ko) 2020-07-29

Family

ID=65526059

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207009046A Ceased KR20200090742A (ko) 2017-08-28 2018-08-28 Il-7 및 il-21에의 il-15 기반 융합

Country Status (8)

Country Link
US (4) US11161890B2 (cg-RX-API-DMAC7.html)
EP (1) EP3676289A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020533971A (cg-RX-API-DMAC7.html)
KR (1) KR20200090742A (cg-RX-API-DMAC7.html)
CN (1) CN111655716B (cg-RX-API-DMAC7.html)
AU (1) AU2018323455B2 (cg-RX-API-DMAC7.html)
CA (1) CA3074635A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019046313A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5501222B2 (ja) * 2007-05-11 2014-05-21 アルター・バイオサイエンス・コーポレーション 融合分子及びｉｌ−１５変異体
JP7136454B2 (ja) * 2017-01-20 2022-09-13 国立大学法人京都大学 ＣＤ８α＋β＋細胞傷害性Ｔ細胞の製造方法
CA3216726C (en) 2017-03-06 2025-08-05 Altor Bioscience Corporation IL-15-BASED FUSION PROTEINS SPECIFIC TO IL-12 AND IL-18
AU2018323455B2 (en) 2017-08-28 2022-02-03 Altor Bioscience, Llc IL-15-based fusions to IL-7 and IL-21
WO2020037120A1 (en) * 2018-08-16 2020-02-20 Nantbio, Inc. Il7-il15 txm compositions and methods
EP4659757A2 (en) 2018-08-30 2025-12-10 ImmunityBio, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3109361A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
JP7407822B2 (ja) 2018-08-30 2024-01-04 エイチシーダブリュー バイオロジックス インコーポレイテッド 単鎖キメラポリペプチドおよびその使用
GB201818816D0 (en) * 2018-11-19 2019-01-02 Synpromics Ltd Regulatory nucleic acid sequences
CN111825770B (zh) * 2019-04-16 2023-06-09 成都医学院 长效白介素21-Fc融合蛋白及其用途
CN114269903B (zh) 2019-06-21 2025-11-25 免疫生物公司 多链嵌合多肽和其用途
GB201909144D0 (en) 2019-06-25 2019-08-07 Autolus Ltd Culture medium
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
WO2021006875A1 (en) * 2019-07-08 2021-01-14 Nantkwest, Inc. Mononuclear cell derived nk cells
WO2021041886A1 (en) * 2019-08-29 2021-03-04 Nantbio, Inc. Modified n-810 and methods therefor
AU2020406083A1 (en) 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
US12115191B2 (en) 2020-02-11 2024-10-15 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
AU2021219720B2 (en) 2020-02-11 2025-10-02 Immunitybio, Inc. Chromatography resin and uses thereof
US12398189B2 (en) 2020-02-11 2025-08-26 HCW Biologics, Inc. Methods of activating regulatory T cells
JP7734693B2 (ja) 2020-04-29 2025-09-05 イミュニティーバイオ インコーポレイテッド 抗ｃｄ２６タンパク質及びそれらの使用法
CA3184756A1 (en) * 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) * 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
GB202008957D0 (en) 2020-06-12 2020-07-29 Autolus Ltd Culture medium
EP4232071A4 (en) 2020-10-23 2024-08-28 Asher Biotherapeutics, Inc. FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
CA3219181A1 (en) 2021-05-19 2022-11-24 Yik Andy Yeung Il-21 polypeptides and targeted constructs
EP4351320A1 (en) 2021-06-09 2024-04-17 ImmunityBio, Inc. Methods and systems for producing a protein of interest in a plant
WO2023278693A1 (en) * 2021-06-30 2023-01-05 The Regents Of The University Of California Altering cytokine specificity through binding valency
CN113549158B (zh) * 2021-07-19 2022-10-21 广州百暨基因科技有限公司 包含突变型il15以及嵌合抗原受体的融合蛋白
CN119546343A (zh) * 2022-04-27 2025-02-28 亚设生物治疗公司 细胞因子融合蛋白与cd8抗原结合分子的组合
WO2024040132A2 (en) * 2022-08-16 2024-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Synergistic interactions for improved cancer treatment
WO2024193705A1 (en) * 2023-03-23 2024-09-26 Analytical Biosciences Shanghai Limited Tnf superfamily member immunocytokine and uses thereof
CN117186243B (zh) * 2023-07-26 2025-08-19 四川三优康生物技术有限公司 猪白细胞介素15，21和23共表达生物制剂材料及应用
WO2025064822A2 (en) * 2023-09-20 2025-03-27 Factor Bioscience Inc. Cells and methods for engineering cells with persistent transgene expression
CN117050178B (zh) * 2023-10-13 2024-01-12 北京百普赛斯生物科技股份有限公司 特异性检测il-7的抗体及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8507A (en) 1851-11-11 petess
US222A (en) 1837-06-10 Truss for the retention and radical cure qe hernia
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
AU5098393A (en) 1992-08-14 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
AU2004289316B2 (en) 2003-11-10 2011-03-31 Altor Bioscience Corporation Soluble TCR molecules and methods of use
JP5501222B2 (ja) * 2007-05-11 2014-05-21 アルター・バイオサイエンス・コーポレーション 融合分子及びｉｌ−１５変異体
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
EP2918607B1 (en) * 2010-09-21 2017-11-08 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
US9724393B2 (en) 2015-10-06 2017-08-08 The Wistar Institute Of Anatomy And Biology Method for treatment of metastatic and refractory cancers and tumors with an inducer that overcomes inhibition of T cell proliferation
CA3200275A1 (en) 2016-10-21 2018-04-26 Nantcell, Inc. Multimeric il-15-based molecules
AU2018323455B2 (en) 2017-08-28 2022-02-03 Altor Bioscience, Llc IL-15-based fusions to IL-7 and IL-21

Also Published As

Publication number Publication date
US11161890B2 (en) 2021-11-02
US11965007B2 (en) 2024-04-23
US12410224B2 (en) 2025-09-09
CN111655716B (zh) 2024-03-08
AU2018323455B2 (en) 2022-02-03
JP2020533971A (ja) 2020-11-26
US20220033455A1 (en) 2022-02-03
AU2018323455A1 (en) 2020-03-19
WO2019046313A1 (en) 2019-03-07
US20190300591A1 (en) 2019-10-03
CA3074635A1 (en) 2019-03-07
EP3676289A1 (en) 2020-07-08
CN111655716A (zh) 2020-09-11
US20240368237A1 (en) 2024-11-07
EP3676289A4 (en) 2021-05-05
US20240076340A1 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
AU2018323455B2 (en) IL-15-based fusions to IL-7 and IL-21
JP7720950B2 (ja) Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合
US11318201B2 (en) Multimeric IL-15-based molecules
EP3464352B1 (en) Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
CN111867612A (zh) 抗PDL1、IL-15和TGF-β受体组合分子
TW201834683A (zh) 與靶向4-1bb (cd137)促效劑併用之組合療法
HK40007105A (en) Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
HK40007105B (en) Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
HK40014316B (en) Multimeric il-15-based molecules
HK40014316A (en) Multimeric il-15-based molecules

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200327

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20200624

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200715

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220219

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220616

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220219

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I